Sagimet Biosciences (SGMT) Free Cash Flow (2022 - 2026)

Sagimet Biosciences' Free Cash Flow history runs 5 years deep, the most recent figure standing at -$8.6 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 40.76% year-over-year to -$8.6 million in Q1 2026; TTM through Mar 2026 was -$39.7 million, a 21.74% increase from a year earlier, with the FY2025 full-year figure at -$45.6 million, down 7.58% from the prior year.
• Free Cash Flow advanced to -$8.6 million in Q1 2026 per SGMT's latest filing, from -$11.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$3000.0 in Q2 2022 and bottomed at -$19.6 million in Q3 2024.
• The 5-year median for Free Cash Flow is -$7.3 million (2022), against an average of -$8.4 million.
• Across the five-year window, Free Cash Flow slumped 190566.67% in 2023 and jumped 47.98% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$7.5 million in 2022, then climbed by 4.96% to -$7.1 million in 2023, then sank by 55.64% to -$11.0 million in 2024, then retreated by 7.34% to -$11.8 million in 2025, then gained by 27.23% to -$8.6 million in 2026.
• Per Business Quant, the three latest SGMT Free Cash Flow figures stand at -$8.6 million (Q1 2026), -$11.8 million (Q4 2025), and -$10.2 million (Q3 2025).